Evotec AG today reported financial results and corporate updates for the first half of 2013. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-h1-2013-results-5151
Evotec and Dow AgroSciences announce collaboration on Cellular Target Profiling
Evotec AG today announced that Evotec and Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company, have entered into a research collaboration with the objective of leveraging Evotec’s advanced chemical proteomics services to support compounds in development at Dow AgroSciences. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-dow-agrosciences-announce-collaboration-on-cellular-target-profiling-5147
Evotec to realign Discovery Chemistry Operations
Evotec AG today announced that it will close its Chemistry Operations in Thane, India. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-realign-discovery-chemistry-operations-5145
Evotec and Harvard University to collaborate on development of new class of antibacterials
Evotec AG today announced a research collaboration with Harvard University aimed at discovering and developing novel anti-bacterial agents based on a highly validated target family involved in bacterial cell wall biosynthesis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-harvard-university-to-collaborate-on-development-of-new-class-of-antibacterials-5137
Evotec Q1 2013: Driving Innovation Efficiency
Revenues without milestones increased in the first quarter of 2013 by 5% compared to the first quarter of 2012- Q1 2013 revenues amounted to EUR 17.1 m (2012: EUR 20.1 m); up 5% compared to Q1 2012 revenues of EUR 16.2 m on a … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-q1-2013-driving-innovation-efficiency-5135
Dana-Farber's Belfer Institute for Applied Cancer Science and Evotec establish collaboration in oncology
The Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute and Evotec AG today announced a research collaboration aimed at discovering and commercialising novel cancer treatments based on epigenetic drug mechanisms. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/dana-farbers-belfer-institute-for-applied-cancer-science-and-evotec-establish-collaboration-in-oncology-5131
Evotec expands compound management capability to East Coast of the United States
Evotec AG today announced that Evotec (US) Inc. has executed a multi-year lease on a facility specifically designed to expand the offering of its Compound Management Services on the East Coast of the United States. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-compound-management-capability-to-east-coast-of-the-united-states-5129
New hormone to treat diabetes published in 'Cell'
Evotec AG today announced an auspicious step in research from Harvard University. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/new-hormone-to-treat-diabetes-published-in-cell-5127
Evotec extends drug discovery alliance with Genentech
Evotec AG today announced that it has extended its drug discovery alliance with Genentech, a member of the Roche Group, for three additional years. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-extends-drug-discovery-alliance-with-genentech-5125
Forward step by step with Action Plan 2016 – Continued revenue growth – Significant pipeline progress
Evotec AG today reported financial results and corporate updates for the fiscal year ended 31 December 2012. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/forward-step-by-step-with-action-plan-2016—continued-revenue-growth—significant-pipeline-progress-5123